Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349
ACS Medicinal Chemistry Letters2012Vol. 4(1), pp. 103–107
Citations Over TimeTop 23% of 2012 papers
Zhonghua Pei, Elizabeth Blackwood, Lichuan Liu, Shiva Malek, Marcia Belvin, Michael F. T. Koehler, Daniel F. Ortwine, Huifen Chen, Frederick Cohen, Jane R. Kenny, Philippe Bergeron, Kevin Lau, Cuong Q. Ly, Xianrui Zhao, Anthony A. Estrada, Tom Truong, Jennifer Epler, Jim Nonomiya, Lan Trinh, Steve Sideris, John Lesnick, Linda Bao, Ulka Vijapurkar, Sophie Mukadam, Suzanne Tay, Gauri Deshmukh, Yung‐Hsiang Chen, Xiao Ding, Lori S. Friedman, Joseph P. Lyssikatos
Abstract
Aberrant activation of the PI3K-Akt-mTOR signaling pathway has been observed in human tumors and tumor cell lines, indicating that these protein kinases may be attractive therapeutic targets for treating cancer. Optimization of advanced lead 1 culminated in the discovery of clinical development candidate 8h, GDC-0349, a potent and selective ATP-competitive inhibitor of mTOR. GDC-0349 demonstrates pathway modulation and dose-dependent efficacy in mouse xenograft cancer models.
Related Papers
- → Defining the Role of mTOR in Cancer(2007)2,803 cited
- → mTOR-therapy and targeted treatment opportunities in mTOR-related epilepsies associated with cortical malformations(2023)19 cited
- → Achieving cancer cell death with PI3K/mTOR‐targeted therapies(2013)27 cited
- → Data from Enhancing Mammalian Target of Rapamycin (mTOR)–Targeted Cancer Therapy by Preventing mTOR/Raptor Inhibition-Initiated, mTOR/Rictor-Independent Akt Activation(2023)
- → Abstract PO1-24-04: Gedatolisib, a pan-PI3K/mTOR inhibitor, shows superior potency and efficacy relative to other PI3K/AKT/mTOR pathway inhibitors in breast cancer models(2024)